Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).

被引：0

作者：

Lee, Jeeyun

Kim, Seung Tae

Smith, Simon

Mortimer, Peter G.

Loembe, Bienvenu

Hong, Jung

Kozarewa, Iwanka

Pierce, Andrew

Dean, Emma

机构：

[1] Samsung Med Ctr, Seoul, South Korea

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] AstraZeneca Phaemaceut, Alderley Pk, England

[4] AstraZeneca, IMED Biotech Unit, Oncol, Cambridge, England

[5] AstraZeneca, Royston, England

[6] AstraZeneca, Cambridge, England

[7] Univ Manchester, Manchester, Lancs, England

[8] Christie NHS Fdn Trust, Manchester, Lancs, England

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3503

引用

页数：2

共 21 条